Literature DB >> 26332621

Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease.

N Smallwood1, B Le2, D Currow3, L Irving1, J Philip4.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive, incurable illness, which leads to significant morbidity over long periods of time and mortality. Treatment aims to reduce symptoms, improve exercise capacity and quality of life, reduce exacerbations, slow disease progression and reduce mortality. However, breathlessness is common in patients with advanced COPD and remains undertreated. As all reversible causes of breathlessness are being optimally managed, consideration should be given to specific non-pharmacological and pharmacological treatment strategies for breathlessness. Low dose morphine has been shown to reduce safely and effectively breathlessness in patients with severe COPD and refractory dyspnoea. However, despite numerous guidelines recommending opioids in this clinical setting, many barriers limit their uptake by clinicians. Integration of palliative care earlier in the disease course can help to improve symptom control for people with severe COPD and refractory breathlessness. A multidisciplinary approach involving both respiratory and palliative care teams offers a new model of care for these patients.
© 2015 Royal Australasian College of Physicians.

Entities:  

Keywords:  COPD; breathlessness; chronic obstructive pulmonary disease; dyspnoea; morphine; opioid

Mesh:

Substances:

Year:  2015        PMID: 26332621     DOI: 10.1111/imj.12857

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

Review 1.  [Management of refractory breathlessness in patients with advanced disease].

Authors:  C Bausewein
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

2.  [Dyspnea, itching and depression in palliative medicine].

Authors:  M Mücke; R Conrad; M Bleckwenn; H Cuhls; L Radbruch; R Rolke
Journal:  Schmerz       Date:  2016-04       Impact factor: 1.107

3.  Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.

Authors:  Miguel Angel Benítez-Rosario; Inmaculada Rosa-González; Enrique González-Dávila; Emilio Sanz
Journal:  Support Care Cancer       Date:  2018-06-18       Impact factor: 3.603

4.  Underdetection and Undertreatment of Dyspnea in Critically Ill Patients.

Authors:  Eliza R Gentzler; Heather Derry; Daniel J Ouyang; Lindsay Lief; David A Berlin; Cici Jiehui Xu; Paul K Maciejewski; Holly G Prigerson
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

5.  Determinants of long-term opioid prescribing in an urban population: A cross-sectional study.

Authors:  Michael Naughton; Patrick Redmond; Stevo Durbaba; Mark Ashworth; Mariam Molokhia
Journal:  Br J Clin Pharmacol       Date:  2022-02-07       Impact factor: 3.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.